Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG INCB 59872-101

Title
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Principal Investigator
Young Chae
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG INCB 59872-101
Purpose
To find out if the study drug INCB059872 is safe and may have beneficial effects in people who have different types of cancer.
Overview
In this research study we are going to determine how safe and well tolerated the study drug is in participants with different types of cancer. Other reasons for this study are: • To study the effect the study drug has on you and the growth of your cancer • To study the way the study drug enters and leaves your body over time (pharmacokinetics or PKs), both when taken before you have food in your stomach and after you have eaten • To study how the study drug acts on and in your body (pharmacodynamics) • To try to identify a group of subjects who may benefit most from the study drug
Eligibility
Some of the eligibility criteria include:
  • Male or female subjects, age 18 years or older.
  • Presence of measurable disease that has been confirmed by histology or cytology.
  • The subject must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
This study has two parts, the first part is called “dose escalation” (Part 1) and the second is “dose expansion” (Part 2). Dose Escalation (Part 1): Treatment Group A: subjects with blood cancers called, acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Treatment Group B: subjects with solid tumors like small cell lung cancer (SCLC) Dose Expansion (Part 2): Treatment Group A1: subjects with blood cancers like AML or MDS; these subjects will receive the dose of the study drug that was found safe and tolerable in the Treatment Group A of the study. Treatment Group A2: subjects with a blood cancer called myelofibrosis (MF) who will receive a dose of the study drug that was found safe and tolerable in the Treatment Group A of the study. Treatment Group B1: subjects with a solid tumor called small cell lung cancer (SCLC) who will receive a dose of the study drug that was found to be safe and tolerable in the Treatment Group B of the study. Treatment Group B2: subjects with other solid tumors who will receive a dose of the study drug that was found to be safe and tolerable in Treatment Group B of the study.
Contact
Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Young Chae

last updated: 19-Oct-17 07:46 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.